Abcam, ab241467, Anti-SLCO2B1/OATP2B1 antibody [EPR22212] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal SLCO2B1/OATP2B1 antibody. Carrier free. Suitable for Flow Cyt, IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22212,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab241467 is the carrier-free version of
ab222094
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The SLCO2B1 also known as OATP2B1 is a member of the organic anion transporting polypeptides family. It functions as a transporter responsible for mediating the uptake of various drugs hormones and other organic compounds. This protein has a molecular mass of about 80 kDa. SLCO2B1 is primarily expressed in the human intestine and liver with significant presence in the brain lung and placenta. It plays a role in the absorption and clearance of pharmacologically relevant compounds.
Biological function summary
SLCO2B1 regulates the transport of endogenous and exogenous substrates across cell membranes. It does not form part of a larger protein complex but interacts with many substrates such as steroid hormones and therapeutic agents. SLCO2B1 influences how drugs are distributed and eliminated affecting the pharmacokinetics and bioavailability in tissues where it is expressed.
Pathways
SLCO2B1 integrates into processes related to drug metabolism and transport. It is important in the absorption and elimination phases within the pharmacokinetic pathway and has a role in the metabolism of steroid hormones. In this context SLCO2B1 cooperates with other transporters and metabolizing enzymes including cytochrome P450s to control the intracellular concentration of various substances.
SLCO2B1 plays a role in influencing drug efficacy and toxicity impacting personalized medicine approaches for individuals with specific genetic transporter variants. SLCO2B1 has implications in cardiovascular diseases related to the pharmacological metabolism of drugs affecting heart rhythm. Additionally its function in hormone regulation connects it with metabolic disorders. In these diseases SLCO2B1 interacts with proteins like MDR1 which also impact drug transport and resistance.